Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE-HAIC + lenvatinib + tislelizumab for unresectable hepatocellular carcinoma
ChiCTR2300067362Phase 2Recruiting
- Sponsor
- Yibin Second People's Hospital
- Start
- Jan 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenvatinib and tislelizumab in hepatocellular carcinoma (HCC), sponsored by Yibin Second People's Hospital. Primary endpoints: Objective response rate and Disease control rate. Started Jan 2023; status: recruiting.
02
Drugs
lenvatinibtislelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2300067362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300067362.